Engineered anti-IL-23p19 antibodies
View Patent ↗Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
1. An isolated binding compound that binds to human IL-23, comprising:
a) an antibody light chain variable region, or antigen binding fragment thereof, comprising:
CDRL1 comprising residues 24-34 of SEQ ID NO: 131;
CDRL2 comprising residues 50-56 of SEQ ID NO: 131;
CDRL3 comprising residues 89-97 of SEQ ID NO: 131; and
b) an antibody heavy chain variable region, or antigen binding fragment thereof, comprising:
CDRH1 comprising residues 26-35 of SEQ ID NO: 130;
CDRH2 comprising residues 50-66 of a sequence selected from the group consisting of SEQ ID NOs: 99, 129 and 130; and
CDRH3 comprising residues 99-104 of SEQ ID NO: 130.
2. The binding compound of claim 1 , wherein the binding compound is an antibody or antigen binding fragment thereof.
3. The binding compound of claim 1 , wherein the binding compound is an antibody or antigen binding fragment thereof comprising:
a) an antibody light chain variable region, or antigen binding fragment thereof, comprising the sequence of SEQ ID NO: 131; and
b) an antibody heavy chain variable region, or antigen binding fragment thereof, comprising the sequence of SEQ ID NO: 129, 130, 132 or 133.
4. The binding compound of claim 3 , wherein the binding compound is an antibody or antigen binding fragment thereof comprising:
a) a light chain variable region comprising the sequence of SEQ ID NO: 131; and
b) a heavy chain variable region comprising the sequence of SEQ ID NO: 130.
5. The isolated binding compound of claim 1 , wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , and a diabody.
6. An isolated antibody, or antigen binding fragment thereof, that is able to block binding of a binding compound to human IL-23 in a cross-blocking assay, wherein the binding compound comprises:
a) a light chain variable region comprising the sequence of SEQ ID NO: 131; and
b) a heavy chain variable region comprising the sequence of SEQ ID NO: 130.
7. The binding compound of claim 6 wherein the binding compound blocks IL-23 mediated activity.